Grantham, Mayo, Van Otterloo & Co (GMO)
CORT icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Corcept Therapeutics CORT Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-14,900
Closed -$177K – 766
2020
Q1 		$177K Buy
+14,900
New +$184K ﹤0.01% 708

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Grantham, Mayo, Van Otterloo & Co (GMO)'s CORT Position: Q2 2020 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Corcept Therapeutics (CORT) in Q2 2020, closing a stake of 14,900 shares — an estimated $177K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in CORT in Q1 2020 and held it in 1 quarter. The position peaked at $177K in Q1 2020. 224 funds tracked by Wall St. Rank hold CORT as of Q2 2020.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Corcept Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 14,900 Corcept Therapeutics shares in Q2 2020, an estimated $177K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Corcept Therapeutics in Q1 2020 and held it in 1 quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Corcept Therapeutics position peaked at $177K in Q1 2020.
  • 224 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2020.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2020, filed 13 Aug 2020.